Beovu Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

beovu

novartis europharm limited  - brolucizumab - wet macular degeneration - augnlækningar - beovu er ætlað í fullorðnir fyrir meðferð neovascular (blautur) aldri-tengjast ský á auga (rÍsa).

Zolgensma Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

zolgensma

novartis europharm limited  - onasemnogene abeparvovec - vöðvaáfall, mænu - Önnur lyf við sjúkdómum í stoðkerfi - zolgensma er ætlað fyrir meðferð:sjúklingar með 5q hrygg vöðvastæltur rýrnun (minni) með bi allelic stökkbreytingu í smn1 gene og klínískum greiningu á minni tegund 1, orpatients með 5q minni með bi allelic stökkbreytingu í smn1 gene og upp að 3 afrit af smn2 gene.

Bemrist Breezhaler Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

bemrist breezhaler

novartis europharm limited  - indacaterol, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Adakveo Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

adakveo

novartis europharm limited - crizanlizumab - blóðleysi, blóðkorn - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Leqvio Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid breytandi lyf - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Jalra Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

jalra

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Zomarist Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

zomarist

novartis europharm limited  - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Oslif Breezhaler Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

oslif breezhaler

novartis europharm limited  - indacaterol maleat - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - oslif skammtur er ætlað fyrir viðhald berkjuvíkkandi meðferð loftstreymi hindrun í fullorðinn sjúklinga með langvinn veikindi í lungum.

Pylobactell Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

pylobactell

torbet laboratories ireland limited - urea (13c) - breath tests; helicobacter infections - greiningarefni - Þetta lyf er eingöngu ætlað til greiningar. fyrir í lífinu greiningu á maga helicobacter haf (h. haf) sýkingu.